Aristea Therapeutics is a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases. The Aristea team is leveraging its broad industry expertise and proven success in drug development to form synergistic partnerships and build a pipeline of novel drugs. Aristea's lead program, RIST4721, is currently in Phase 2 clinical development.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/18/18 | $15,000,000 | Series A |
Novo Holdings | undisclosed |
